Adial Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 6.04 million shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2022-11-14
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-06-30 was 0.00 shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-03-31 was 6.04M shares, a 29964.12% increase year-over-year.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2021-12-31 was 0.00 shares.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 53.15K shares, a 97.59% decline from fiscal 2020.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2020 was 2.21M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|---|
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 6.04M shares 10-Q · filed 2022-11-14 | 6.04M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 6.04M shares 10-Q · filed 2022-08-15 | 6.04M shares derived: sum of 3 quarters · filed 2022-08-15 | 6.08M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 6.04M shares 10-Q · filed 2022-05-16 | 6.04M shares derived: sum of 2 quarters · filed 2022-05-16 | 6.08M shares derived: sum of 3 quarters · filed 2022-05-16 | 6.08M shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 33.05K shares derived: sum of 2 quarters · filed 2022-03-28 | 33.05K shares derived: sum of 3 quarters · filed 2022-03-28 | 53.15K shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 33.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 33.05K shares derived: sum of 2 quarters · filed 2021-11-15 | 53.15K shares 10-Q · filed 2021-11-15 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 20.10K shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 20.10K shares 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 2.21M shares 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |